Clinuvel Pharmaceuticals vs Enanta Pharmaceuticals
Clinuvel Pharmaceuticals and Enanta Pharmaceuticals are similar in size: $64.3m and $65.3m of revenue in their latest fiscal years. Clinuvel Pharmaceuticals grew faster (5.2% against -3.4%). Clinuvel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.0% against -125.4%. Clinuvel Pharmaceuticals carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Clinuvel PharmaceuticalsCUVL, 2026 | Enanta PharmaceuticalsENTA, 2025 |
|---|---|---|
| Revenue | $64.3m | $65.3m |
| Revenue growth | 5.2% | -3.4% |
| Net income | $23.2m | −$81.9m |
| Operating margin | 43.4% | -130.7% |
| Net margin | 36.0% | -125.4% |
| Return on equity | 13.4% | -84.6% |
| Free cash flow | $11.8m | −$32.2m |
| Cash | $13.9m | $32.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 120 |
| Market value | $256m | $305m |
| Price vs our value range | — | — |
| Moat score | — | 17 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 9 sales |